Middle East Healthcare Company

SASE:4009 Voorraadrapport

Marktkapitalisatie: ر.س6.5b

Middle East Healthcare Inkomsten in het verleden

Verleden criteriumcontroles 4/6

Middle East Healthcare is de winst gegroeid met een gemiddeld jaarlijks percentage van 20.8%, terwijl de Healthcare industrie de winst jaarlijks groeide met 20.3%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 13.8% per jaar. Het rendement op eigen vermogen van Middle East Healthcare is 12.1%, en het heeft een nettomarge van 7.4%.

Belangrijke informatie

20.8%

Groei van de winst

20.8%

Groei van de winst per aandeel

Healthcare Groei van de industrie12.3%
Inkomstengroei13.8%
Rendement op eigen vermogen12.1%
Nettomarge7.4%
Laatste winstupdate30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

Investors Will Want Middle East Healthcare's (TADAWUL:4009) Growth In ROCE To Persist

Sep 24
Investors Will Want Middle East Healthcare's (TADAWUL:4009) Growth In ROCE To Persist

Middle East Healthcare Company (TADAWUL:4009) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Aug 09
Middle East Healthcare Company (TADAWUL:4009) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Middle East Healthcare Company's (TADAWUL:4009) Price In Tune With Earnings

Jul 18
Middle East Healthcare Company's (TADAWUL:4009) Price In Tune With Earnings

There's Been No Shortage Of Growth Recently For Middle East Healthcare's (TADAWUL:4009) Returns On Capital

May 30
There's Been No Shortage Of Growth Recently For Middle East Healthcare's (TADAWUL:4009) Returns On Capital

Middle East Healthcare Company Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

May 09
Middle East Healthcare Company Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

If EPS Growth Is Important To You, Middle East Healthcare (TADAWUL:4009) Presents An Opportunity

Apr 29
If EPS Growth Is Important To You, Middle East Healthcare (TADAWUL:4009) Presents An Opportunity

Why Investors Shouldn't Be Surprised By Middle East Healthcare Company's (TADAWUL:4009) 27% Share Price Plunge

Apr 02
Why Investors Shouldn't Be Surprised By Middle East Healthcare Company's (TADAWUL:4009) 27% Share Price Plunge

There's Reason For Concern Over Middle East Healthcare Company's (TADAWUL:4009) Massive 40% Price Jump

Feb 11
There's Reason For Concern Over Middle East Healthcare Company's (TADAWUL:4009) Massive 40% Price Jump

Returns On Capital At Middle East Healthcare (TADAWUL:4009) Have Stalled

Feb 08
Returns On Capital At Middle East Healthcare (TADAWUL:4009) Have Stalled

Should You Be Adding Middle East Healthcare (TADAWUL:4009) To Your Watchlist Today?

Jan 18
Should You Be Adding Middle East Healthcare (TADAWUL:4009) To Your Watchlist Today?

Middle East Healthcare Company's (TADAWUL:4009) Revenues Are Not Doing Enough For Some Investors

Dec 28
Middle East Healthcare Company's (TADAWUL:4009) Revenues Are Not Doing Enough For Some Investors

Middle East Healthcare (TADAWUL:4009) Will Want To Turn Around Its Return Trends

Sep 26
Middle East Healthcare (TADAWUL:4009) Will Want To Turn Around Its Return Trends

Some Investors May Be Worried About Middle East Healthcare's (TADAWUL:4009) Returns On Capital

Jun 28
Some Investors May Be Worried About Middle East Healthcare's (TADAWUL:4009) Returns On Capital

Investors Could Be Concerned With Middle East Healthcare's (TADAWUL:4009) Returns On Capital

Mar 30
Investors Could Be Concerned With Middle East Healthcare's (TADAWUL:4009) Returns On Capital

Capital Allocation Trends At Middle East Healthcare (TADAWUL:4009) Aren't Ideal

Sep 20
Capital Allocation Trends At Middle East Healthcare (TADAWUL:4009) Aren't Ideal

Calculating The Intrinsic Value Of Middle East Healthcare Company (TADAWUL:4009)

Jun 14
Calculating The Intrinsic Value Of Middle East Healthcare Company (TADAWUL:4009)

Returns On Capital At Middle East Healthcare (TADAWUL:4009) Paint A Concerning Picture

Apr 18
Returns On Capital At Middle East Healthcare (TADAWUL:4009) Paint A Concerning Picture

Here's What's Concerning About Middle East Healthcare's (TADAWUL:4009) Returns On Capital

Aug 10
Here's What's Concerning About Middle East Healthcare's (TADAWUL:4009) Returns On Capital

Middle East Healthcare (TADAWUL:4009) Will Will Want To Turn Around Its Return Trends

Mar 29
Middle East Healthcare (TADAWUL:4009) Will Will Want To Turn Around Its Return Trends

An Intrinsic Calculation For Middle East Healthcare Company (TADAWUL:4009) Suggests It's 28% Undervalued

Mar 03
An Intrinsic Calculation For Middle East Healthcare Company (TADAWUL:4009) Suggests It's 28% Undervalued

Are Middle East Healthcare's (TADAWUL:4009) Statutory Earnings A Good Guide To Its Underlying Profitability?

Feb 10
Are Middle East Healthcare's (TADAWUL:4009) Statutory Earnings A Good Guide To Its Underlying Profitability?

Weak Financial Prospects Seem To Be Dragging Down Middle East Healthcare Company (TADAWUL:4009) Stock

Jan 23
Weak Financial Prospects Seem To Be Dragging Down Middle East Healthcare Company (TADAWUL:4009) Stock

If You Had Bought Middle East Healthcare's (TADAWUL:4009) Shares Three Years Ago You Would Be Down 38%

Jan 05
If You Had Bought Middle East Healthcare's (TADAWUL:4009) Shares Three Years Ago You Would Be Down 38%

Should You Be Impressed By Middle East Healthcare's (TADAWUL:4009) Returns on Capital?

Dec 18
Should You Be Impressed By Middle East Healthcare's (TADAWUL:4009) Returns on Capital?

Calculating The Fair Value Of Middle East Healthcare Company (TADAWUL:4009)

Nov 30
Calculating The Fair Value Of Middle East Healthcare Company (TADAWUL:4009)

Opbrengsten en kosten

Hoe Middle East Healthcare geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

SASE:4009 Opbrengsten, kosten en inkomsten (SAR Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Sep 242,8542116890
30 Jun 242,7932036680
31 Mar 242,7041826540
31 Dec 232,6531806610
30 Sep 232,5511776030
30 Jun 232,3931355740
31 Mar 232,2761055510
31 Dec 222,152755320
30 Sep 222,033245470
30 Jun 222,019275690
31 Mar 221,968265650
31 Dec 211,873175410
30 Sep 211,823454930
30 Jun 211,816664740
31 Mar 211,733734380
31 Dec 201,751824540
30 Sep 201,7081104430
30 Jun 201,6031084000
31 Mar 201,5831043990
31 Dec 191,497983600
30 Sep 191,401913410
30 Jun 191,353783440
31 Mar 191,3461003350
31 Dec 181,3911723260
30 Sep 181,4452243170
30 Jun 181,4592693040
31 Mar 181,4642973000
31 Dec 171,4623192970
30 Sep 171,5033223420
30 Jun 171,5293563720
31 Mar 171,5883684260
31 Dec 161,6163634660
30 Sep 161,6293804620
30 Jun 161,6023714480
31 Mar 161,5643894250
31 Dec 151,5353904180
30 Sep 151,4853734130
30 Jun 151,4563564240
31 Mar 151,4313574050
31 Dec 141,3993324240
31 Dec 138281372850

Kwaliteitswinsten: 4009 heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (7.4%) 4009 } zijn hoger dan vorig jaar (6.9%).


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: De winst van 4009 is de afgelopen 5 jaar aanzienlijk gegroeid met 20.8% per jaar.

Versnelling van de groei: De winstgroei van 4009 over het afgelopen jaar ( 19.5% ) ligt onder het 5-jarig gemiddelde ( 20.8% per jaar).

Winst versus industrie: De winstgroei 4009 over het afgelopen jaar ( 19.5% ) overtrof de Healthcare -sector 15.7%.


Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 12.1% ) van 4009 wordt als laag beschouwd.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden